株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のワクチン市場・予測 (14ヶ国の市場データ)

Global Vaccines Market & Forecast (14 Vaccines Market, Number of People Immunized Doses of Vaccines Administered)

発行 Renub Research 商品コード 543298
出版日 ページ情報 英文 318 Pages; 193 Figures; 44 Tables
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.47円で換算しております。
Back to Top
世界のワクチン市場・予測 (14ヶ国の市場データ) Global Vaccines Market & Forecast (14 Vaccines Market, Number of People Immunized Doses of Vaccines Administered)
出版日: 2017年08月16日 ページ情報: 英文 318 Pages; 193 Figures; 44 Tables
概要

世界のワクチン市場規模は、2022年までに600億米ドルへ達すると予測されています。2022年までに小児用ワクチン市場のシェアは成人用ワクチン市場シェアの2倍の規模となる見込みです。乳児に投与されるロタウィルスワクチンの投与量は、今後増加すると予測され、2022年までに約1,500万へ達する見込みです。

当レポートでは、世界のワクチン市場 (主要14ヶ国) について調査分析し、成人・小児用ワクチン市場の分析と予測、予防接種人口の分析と予測、疾患別によるワクチン投与量の分析と予測、および主要企業のプロファイルなどをまとめています。

第1章 調査結果

第2章 世界のワクチン市場・予測

  • 成人用ワクチン市場・予測
  • 小児用ワクチン市場・予測

第3章 世界の成人用ワクチン vs. 小児用ワクチン市場シェア

第4章 世界のワクチン市場シェア・予測

  • 成人用ワクチン市場シェア・予測
  • 小児用ワクチン市場シェア・予測

第5章 世界の予防接種人口・予測

  • 成人予防接種人口・予測
  • 小児予防接種人口・予測

第6章 世界の予防接種人口シェア・予測

  • 成人予防接種人口シェア・予測
  • 小児予防接種人口シェア・予測

第7章 世界のワクチン投与量・予測

  • 成人用ワクチン投与量・予測
  • 小児用ワクチン投与量・予測

第8章 世界のワクチン投与量シェア・予測

  • 成人用ワクチン投与量シェア・予測
  • 小児用ワクチン投与量シェア・予測

第9章 世界のワクチン企業の市場シェア・予測

第10章 疾患別によるワクチン市場・予測

  • インフルエンザ
  • 子宮頸癌 (HPV):ワクチン市場・予測
  • 帯状疱疹:ワクチン市場・予測
  • MMRV・MMR (麻しん、流行性耳下腺炎、風疹、および水痘ワクチン) :ワクチン市場・予測
  • 肺炎球菌:ワクチン市場・予測
  • 髄膜炎:ワクチン市場・予測
  • 肝炎:ワクチン市場・予測
  • TdaP・DTaP (破傷風、ジフテリア、百日咳) :ワクチン市場・予測
  • インフルエンザB型:ワクチン市場・予測
  • 併用ワクチン:ワクチン市場・予測
  • ポリオ:ワクチン市場・予測
  • ロタウィルス:ワクチン市場・予測
  • 水痘:ワクチン市場・予測

第11章 疾患別による予防接種者数・予測

第12章 疾患別によるワクチン投与量・予測

第13章 疾患別による予防接種プロファイル

  • 乳児の予防接種率
  • 世界の予防接種プロファイル
  • 地域の予防接種プロファイル

第14章 ワクチン主要企業の売上・予測

  • GlaxoSmithKline, plc.:ワクチン売上・予測
  • Merck & Co.:ワクチン売上・予測
  • Sanofi Pasteur:ワクチン売上・予測
  • Worldwide-Pfizer, Inc.:ワクチン売上・予測
  • その他のワクチン売上・予測

第15章 ワクチン:製品・パイプライン

  • GSK
  • Merck
  • Sanofi
  • Pfizer

第16章 ワクチン産業における主なM&A

第17章 ワクチンおよび規制当局の介入

第18章 ワクチン市場の促進因子

  • 先刻的な予防接種スケジュールへ組み込む
  • HPVワクチンの予防接種率が増加
  • 感染症有病率の増加
  • 世界の予防接種に関する展望と戦略 (GIVS)
  • GIVSモデルがワクチンメーカーを刺激、ほか

第19章 ワクチン市場の課題

  • 認可済みワクチンの最適な利用における生涯
  • 複雑なワクチン開発 & 認可システムが製品開発を妨害
  • ワクチン開発スケジュールの短縮、ほか

図表リスト

目次

Global Vaccines Market to reach US$ 60 Billion by the year 2022. Pediatric vaccines market is having a dominant market share compared to Adult vaccines market. By 2022 Pediatric vaccines market share will be double the size of adult vaccines market share. Worldwide the number of infants immunized by influenza vaccines remain considerably low than that of adults immunized in year 2017. While the number of Rotavirus doses administered in infants is forecast to increase over the years and reach nearly 15 Million by the year 2022.

Adult Vaccine Market Share Analysis

Out of the total 9 Adult vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel) studied in the report Influenza vaccines dominates the adult vaccine market in 2017.

Pediatric Vaccine Market Share Analysis

Our analysis found that in year 2017; Pneumococcal and Combination vaccine together accounts for nearly 50% of the pediatric vaccine market share. Other Pediatric vaccines market studied in the report are as follows: Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Haemophilus Influenzae Type b(Hib), Combos, Polio, Rotavirus, Varicella.

In 2017 Combos Vaccines will control the Immunization Share

For the year 2017; Combos (Combination Vaccines) has the maximum immunization share among all pediatric vaccines (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Haemophilus Influenzae Type b(Hib), Polio, Rotavirus, Varicella) studied in the report as they protect against more ailments in single shot, people preferring to get combination vaccine instead of a specific vaccine.

Administration of Vaccine Doses

Our analysis found that there is a consistent surge in the number of Pneumococcal and Meningococcal vaccine doses administration in future due to the rising concern against the life-threatening vaccine-preventable diseases around the world.

‘Global Vaccines Market & Forecast (14 Vaccines Market, Number of People Immunized Doses of Vaccines Administered) ’ is the 8th edition of market research report published by Renub Research on Global Vaccines Market. This is a 318 page report with 193 Figures and 44 Tables provides data of Global Vaccine Market (Adult & Pediatrics), People Immunized, Number of Vaccine Doses Administered (Disease wise) & Key Players. Vaccine has been extensively studied from 3 major points, and further sub-divided into 2 more points:

1. World Vaccines (Disease wise) Market & Forecast (2011 - 2022)

  • a. Adult Vaccines Market & Forecast
  • b. Pediatrics Vaccines Market & Forecast

2. People Immunized (Disease wise) & Forecast (2011 - 2022)

  • a. Adult Immunized & Forecast
  • b. Pediatric (Infants) Immunized & Forecast

3. Doses of Vaccines Administered (Disease wise) & Forecast (2011 - 2022)

  • a. Doses of vaccines administered in Adults & Forecast
  • b. Doses of vaccines administered in Pediatric (Infants) & Forecast

14 Vaccines Studied in the Report are as Follows:

  • 1. Influenza
  • 2. Cervical Cancer
  • 3. Zoster (Shingles)
  • 4. MMR (Measles, Mumps, and Rubella)
  • 5. Pneumonia
  • 6. Meningitis
  • 7. Hepatitis
  • 8. Tap (Diphtheria, Tetanus, Pertussis)
  • 9. Haemophilus influenzae type B
  • 10. Polio
  • 11. Rotavirus
  • 12. Varicella
  • 13. Combination Vaccine
  • 14. Travel & Miscellaneous Vaccine

Why This Report a Compulsory Buy!

  • This report offers complete analysis of Disease wise Global Vaccines Market & Forecast (2011 - 2022).
  • This report offers segmented analysis of Disease wise Global Vaccines Market into two segments:
    • Adult Vaccines (Disease wise) Market &Forecast
    • Pediatric (Infant) Vaccines (Disease wise) Market &Forecast
  • This report offers extensive analysis of the number of people Immunized and Number of Vaccines Doses Administered & Forecast (2011 - 2022) by Adult & Pediatric (Infant).
  • This report offers widespread analysis on Vaccine Key Players (Worldwide) & Forecast (2011 - 2022)

Table of Contents

1. Research Findings

2. Global-Vaccines Market and Forecast

  • 2.1. Adult Vaccines Market and Forecast
  • 2.2. Pediatric (Infant) Vaccines Market and Forecast

3. Global-Adult Vaccine vs. Pediatric Vaccine Market Share

4. Global-Vaccines Market Share and Forecast

  • 4.1. Adult Vaccines Market Share and Forecast
  • 4.2. Pediatric (Infant) Vaccines Market Share and Forecast

5. Global-People Immunized and Forecast

  • 5.1. Adult Immunized and Forecast
  • 5.2. Pediatric (Infant) Immunized and Forecast

6. Global-People Immunized Share and Forecast

  • 6.1. Adult Immunized Share and Forecast
  • 6.2. Pediatric (Infant) Immunized Share and Forecast

7. Global-Doses of Vaccines Administered and Forecast

  • 7.1. Doses of Adult Vaccines Administered and Forecast
  • 7.2. Doses of Pediatric (Infant) Vaccines Administered and Forecast

8. Global-Doses of Vaccines Administered Share and Forecast

  • 8.1. Doses of Vaccines Administered to Adult Share and Forecast
  • 8.2. Doses of Vaccines Administered to Pediatric (Infant) Share and Forecast

9. Global-Vaccine Companies Market Share and Forecast

10. Disease wise-Vaccines Market and Forecast

  • 10.1. Influenza-Total Vaccines Market and Forecast
    • 10.1.1. Influenza-Adult Vaccines Market and Forecast
    • 10.1.2. Influenza-Pediatric (Infant) Vaccines Market and Forecast
  • 10.2. Cervical Cancer (HPV)-Vaccines Market and Forecast
  • 10.3. Zoster (Shingles)-Vaccines Market and Forecast
  • 10.4. MMRV and MMR (Measles, Mumps, Rubella, and Varicella Vaccine)-Total Vaccines Market and Forecast
    • 10.4.1. MMRV-Adult Vaccines Market and Forecast
    • 10.4.2. MMR-Pediatric (Infant) Vaccines Market and Forecast
  • 10.5. Pneumococcal-Total Vaccines Market and Forecast
    • 10.5.1. Pneumococcal-Adult Vaccines Market and Forecast
    • 10.5.2. Pneumococcal-Pediatric (Infant) Vaccines Market and Forecast
  • 10.6. Meningococcal-Total Vaccines Market and Forecast
    • 10.6.1. Meningococcal-Adult Vaccines Market and Forecast
    • 10.6.2. Meningococcal-Pediatric (Infant) Vaccines Market and Forecast
  • 10.7. Hepatitis-Total Vaccines Market and Forecast
    • 10.7.1. Hepatitis-Adult Vaccines Market and Forecast
    • 10.7.2. Hepatitis-Pediatric (Infant) Vaccines Market and Forecast
  • 10.8. TdaP and DTaP-Total Vaccines Market and Forecast
    • 10.8.1. TdaP-Adult Vaccines Market and Forecast
    • 10.8.2. DTaP-Pediatric (Infant) Vaccines Market and Forecast
  • 10.9. Travel and Miscellaneous-Vaccines Market and Forecast
  • 10.10. Haemophilus Influenzae Type B (HIB)-Vaccines Market and Forecast
  • 10.11. Combos (Combination)-Vaccines Market and Forecast
  • 10.12. Polio-Vaccines Market and Forecast
  • 10.13. Rotavirus-Vaccines Market and Forecast
  • 10.14. Varicella-Vaccines Market and Forecast

11. Disease wise-People Immunized Numbers and Forecast

  • 11.1. Influenza-Total Number of People Immunized and Forecast
    • 11.1.1. Influenza-Number of Adults Immunized and Forecast
    • 11.1.2. Influenza-Number of Infants Immunized and Forecast
  • 11.2. Cervical Cancer (HPV)-People Immunized and Forecast
  • 11.3. Zoster (Shingles)-Number of People Immunized and Forecast
  • 11.4. MMRV and MMR-Total Number of People Immunized and Forecast
    • 11.4.1. MMRV-Number of Adults Immunized and Forecast
    • 11.4.2. MMR-Number of Pediatric (Infants) Immunized and Forecast
  • 11.5. Pneumococcal-Total Number of People Immunized and Forecast
    • 11.5.1. Pneumococcal-Number of Adults Immunized and Forecast
    • 11.5.2. Pneumococcal-Number of Infants Immunized and Forecast
  • 11.6. Meningococcal-Total Number of People Immunized and Forecast
    • 11.6.1. Meningococcal-Number of Adults Immunized and Forecast
    • 11.6.2. Meningococcal-Number of Infants Immunized and Forecast
  • 11.7. Hepatitis-Total Number of People Immunized and Forecast
    • 11.7.1. Hepatitis-Number of Adults Immunized and Forecast
    • 11.7.2. Hepatitis-Number of Infants Immunized and Forecast
  • 11.8. TdaP and DTaP-Total Number of People Immunized and Forecast
    • 11.8.1. TdaP-Number of Adults Immunized and Forecast
    • 11.8.2. DTaP-Number of Infants Immunized and Forecast
  • 11.9. Hib (Haemophilus Influenzae Type B)-Number of Infants Immunized and Forecast
  • 11.10. Combos (Combination Vaccines)-Number of Infants Immunized and Forecast
  • 11.11. Polio-Number of Infants Immunized and Forecast
  • 11.12. Rotavirus-Number of Infants Immunized and Forecast
  • 11.13. Varicella-Number of Infants Immunized and Forecast

12. Disease wise-Doses of Vaccines Administered and Forecast

  • 12.1. Influenza-Doses of Vaccines Administered and Forecast
    • 12.1.1. Influenza-Doses of Adult Vaccines Administered and Forecast
    • 12.1.2. Influenza-Doses of Infant Vaccines Administered and Forecast
  • 12.2. Cervical Cancer (HPV)-Doses of Vaccines Administered and Forecast
  • 12.3. Zoster (Shingles)-Doses of Vaccines Administered and Forecast
  • 12.4. MMRV and MMR-Doses of Vaccines Administered and Forecast
    • 12.4.1. MMRV-Doses of Adult Vaccines Administered and Forecast
    • 12.4.2. MMR-Doses of Infant Vaccines Administered and Forecast
  • 12.5. Pneumococcal-Doses of Vaccines Administered and Forecast
    • 12.5.1. Pneumococcal-Doses of Adult Vaccines Administered and Forecast
    • 12.5.2. Pneumococcal-Doses of Infant Vaccines Administered and Forecast
  • 12.6. Meningococcal-Doses of Vaccines Administered and Forecast
    • 12.6.1. Meningococcal-Doses of Adult Vaccines Administered and Forecast
    • 12.6.2. Meningococcal-Doses of Infant Vaccines Administered and Forecast
  • 12.7. Hepatitis-Doses of Vaccines Administered and Forecast
    • 12.7.1. Hepatitis-Doses of Adult Vaccines Administered and Forecast
    • 12.7.2. Hepatitis-Doses of Infant Vaccines Administered and Forecast
  • 12.8. TdaP and DTaP-Doses of Vaccines Administered and Forecast
    • 12.8.1. TdaP-Doses of Adult Vaccines Administered and Forecast
    • 12.8.2. DTaP-Doses of Infant Vaccines Administered and Forecast
  • 12.9. Hib (Haemophilus Influenzae Type B)-Doses of Infant Vaccines Administered and Forecast
  • 12.10. Polio-Doses of Infant Vaccines Administered and Forecast
  • 12.11. Rotavirus-Doses of Infant Vaccines Administered and Forecast
  • 12.12. Varicella-Doses of Infant Vaccines Administered and Forecast

13. Disease wise-Immunization Profile

  • 13.1. Immunization Coverage (%) in Infants (2005-2015)
  • 13.2. Global Immunization Profile (2011-2015)
  • 13.3. Regional Immunization Profile (2001-2015)
    • 13.3.1. Measles-Number of Cases Reported
    • 13.3.2. Mumps-Number of Cases Reported
    • 13.3.3. Rubella-Number of Cases Reported
    • 13.3.4. Rubella (CRS)-Number of Cases Reported
    • 13.3.5. Diphtheria-Number of Cases Reported
    • 13.3.6. Tetanus (Neonatal)-Number of Cases Reported
    • 13.3.7. Tetanus (Total)-Number of Cases Reported
    • 13.3.8. Pertussis-Number of Cases Reported
    • 13.3.9. Polio-Number of Cases Reported
    • 13.3.10. Yellow Fever-Number of Cases Reported
    • 13.3.11. Japanese encephalitis-Number of Cases Reported, 2006-2015

14. Vaccines Key Players Sales and Forecast

  • 14.1. GlaxoSmithKline, plc.'s Vaccines Sales and Forecast
  • 14.2. Merck & Co. Vaccines Sales and Forecast
  • 14.3. Sanofi Pasteur's Vaccines Sales and Forecast
  • 14.4. Worldwide-Pfizer, Inc.'s Vaccines Sales and Forecast
  • 14.5. Worldwide-Others Vaccines Sales and Forecast

15. Vaccines-Products and Pipeline

  • 15.1. GSK Vaccine Product Pipeline
  • 15.2. Merck Vaccine Product Pipeline
  • 15.3. Sanofi Vaccine Product Pipeline
  • 15.4. Pfizer Vaccine Product Pipeline

16. Top Mergers and Acquisitions in the Vaccine Industry

17. Vaccines and Regulator's Interventions

  • 17.1. Making and Meeting Standards of Quality and Safety
  • 17.2. Vaccine Funding

18. Vaccine Market Drivers

  • 18.1. Inclusion in National Immunization Schedule
  • 18.2. Growing Immunization Coverage for HPV Vaccines
  • 18.3. Increase in Prevalence of Infectious Diseases
  • 18.4. Global Immunization Vision and Strategy (GIVS)
  • 18.5. GAVI Model Fuelling Vaccine Manufacturers
    • 18.5.1. The Partnership Model
    • 18.5.2. The Business Model
  • 18.6. Increasing Vaccine Availability in United States
  • 18.7. The Vaccine Safety Data link Project
  • 18.8. The Vaccine Injury Compensation Program
  • 18.9. Transforming of Vaccine Technologies
  • 18.10. Global Vaccine Action Plan by WHO (2011-2020)
  • 18.11. Continuous Focus on Effective Communication Strategies

19. Vaccines Market Challenges

  • 19.1. Hurdles to Optimal use of Licensed Vaccines
    • 19.1.1. Technical Obstacles
    • 19.1.2. Economic Obstacles
    • 19.1.3. Cultural Obstacles
  • 19.2. Complexity of Vaccine Development & Approval System Thwarts Product Development
    • 19.2.1. Legal Obstacles
    • 19.2.2. General Technical Barriers
    • 19.2.3. Economic Barriers
    • 19.2.4. Regulatory Barriers
  • 19.3. Shortening the Timeline for Vaccine Development
  • 19.4. Refusal/Resistance to Vaccination
    • 19.4.1. Vaccine Adverse Event Reporting System
  • 19.5. Vaccine Shortages and Delays
  • 19.6. Obstacles in Vaccine Research & Development
  • 19.7. Barriers to New Entrants in the Vaccines Market

List of Figures

  • Figure 2-1: Global-Vaccines Market (Billion US$), 2011-2016
  • Figure 2-2: Global-Forecast for Vaccines Market (Billion US$), 2017-2022
  • Figure 2-3: Global-Adult Vaccines Market (Billion US$), 2011-2016
  • Figure 2-4: Global-Forecast for Adult Vaccines Market (Billion US$), 2017-2022
  • Figure 2-5: Global-Pediatric (Infant) Vaccines Market (Billion US$), 2011-2016
  • Figure 2-6: Global-Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2017-2022
  • Figure 3-1: Global-Adult Vs. Pediatric Vaccine Market Share
  • Figure 3-2: Global-Forecast for Adult Vs. Pediatric Vaccine Market Share
  • Figure 5-1: Global-People Immunized (Million), 2011-2016
  • Figure 5-2: Global-People Immunized (Million), 2017-2022
  • Figure 5-3: Global-Adult Immunized (Million), 2011-2016
  • Figure 5-4: Global-Forecast for Adult Immunized (Million), 2017-2022
  • Figure 5-5: Global-Pediatric (Infant) Immunized (Million), 2011-2016
  • Figure 5-6: Global-Forecast for Pediatric (Infant) Immunized (Million), 2017-2022
  • Figure 7-1: Global-Doses of Vaccines Administered (Million), 2011-2016
  • Figure 7-2: Global-Forecast for Doses of Vaccines Administered (Million), 2017-2022
  • Figure 7-3: Global-Doses of Adult Vaccines Administered (Million), 2011-2016
  • Figure 7-4: Global-Forecast for Doses of Adult Vaccines Administered (Million), 2017-2022
  • Figure 7-5: Global-Doses of Pediatric (Infant) Vaccines Administered (Million), 2011-2016
  • Figure 7-6: Global-Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2017-2022
  • Figure 9-1: Global-Key Players Vaccines Market Share (Percent), 2011-2016
  • Figure 9-2: Global-Forecast for Key Players Vaccines Market Share (Percent), 2017-2022
  • Figure 10-1: Influenza-Total Vaccines Market (Billion US$), 2011-2016
  • Figure 10-2: Influenza-Forecast for Total Vaccines Market (Billion US$), 2017-2022
  • Figure 10-3: Influenza-Adult Vaccines Market (Billion US$), 2011-2016
  • Figure 10-4: Influenza-Forecast for Adult Vaccines Market (Billion US$), 2017-2022
  • Figure 10-5: Influenza-Pediatric (Infant) Vaccines Market (Million US$), 2011-2016
  • Figure 10-6: Influenza-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017-2022
  • Figure 10-7: Cervical Cancer (HPV)-Vaccines Market (Billion US$), 2011-2016
  • Figure 10-8: Cervical Cancer (HPV)-Forecast for Vaccines Market (Billion US$), 2017-2022
  • Figure 10-9: Zoster (Shingles)-Vaccines Market (Billion US$), 2011-2016
  • Figure 10-10: Zoster (Shingles)-Forecast for Vaccines Market (Billion US$), 2017-2022
  • Figure 10-11: MMRV and MMR-Total Vaccines Market (Billion US$), 2011-2016
  • Figure 10-12: MMRV and MMR-Forecast for Total Vaccines Market (Billion US$), 2017-2022
  • Figure 10-13: MMRV-Adult Vaccines Market (Million US$), 2011-2016
  • Figure 10-14: MMRV-Forecast for Adult Vaccines Market (Million US$), 2017-2022
  • Figure 10-15: MMR-Pediatric (Infant) Vaccines Market (Million US$), 2011-2016
  • Figure 10-16: MMR-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017-2022
  • Figure 10-17: Pneumococcal-Total Vaccines Market (Billion US$), 2011-2016
  • Figure 10-18: Pneumococcal-Forecast for Total Vaccines Market (Billion US$), 2017-2022
  • Figure 10-19: Pneumococcal-Adult Vaccines Market (Billion US$), 2011-2016
  • Figure 10-20: Pneumococcal-Forecast for Adult Vaccines Market (Billion US$), 2017-2022
  • Figure 10-21: Pneumococcal-Pediatric (Infant) Vaccines Market (Billion US$), 2011-2016
  • Figure 10-22: Pneumococcal-Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2017-2022
  • Figure 10-23: Areas with frequent epidemics of meningococcal meningitis
  • Figure 10-24: Meningococcal-Total Vaccines Market (Billion US$), 2011-2016
  • Figure 10-25: Meningococcal-Forecast for Total Vaccines Market (Billion US$), 2017-2022
  • Figure 10-26: Meningococcal-Adult Vaccines Market (Million US$), 2011-2016
  • Figure 10-27: Meningococcal-Forecast for Adult Vaccines Market (Million US$), 2017-2022
  • Figure 10-28: Meningococcal-Pediatric (Infant) Vaccines Market (Million US$), 2011-2016
  • Figure 10-29: Meningococcal-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017-2022
  • Figure 10-30: Hepatitis-Total Vaccines Market (Billion US$), 2011-2016
  • Figure 10-31: Hepatitis-Forecast for Total Vaccines Market (Billion US$), 2017-2022
  • Figure 10-32: Hepatitis-Adult Vaccines Market (Billion US$), 2011-2016
  • Figure 10-33: Hepatitis-Forecast for Adult Vaccines Market (Billion US$), 2017-2022
  • Figure 10-34: Hepatitis-Pediatric (Infant) Vaccines Market (Million US$), 2011-2016
  • Figure 10-35: Hepatitis-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017-2022
  • Figure 10-36: TdaP and DTaP-Total Vaccines Market (Billion US$), 2011-2016
  • Figure 10-37: TdaP and DTaP-Forecast for Total Vaccines Market (Billion US$), 2017-2022
  • Figure 10-38: TdaP-Adult Vaccines Market (Million US$), 2011-2016
  • Figure 10-39: TdaP-Forecast for Adult Vaccines Market (Million US$), 2017-2022
  • Figure 10-40: DTaP-Pediatric (Infant) Vaccines Market (Million US$), 2011-2016
  • Figure 10-41: DTaP-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017-2022
  • Figure 10-42: Travel and Miscellaneous-Vaccines Market (Billion US$), 2011-2016
  • Figure 10-43: Travel and Miscellaneous-Forecast for Vaccines Market (Billion US$), 2017-2022
  • Figure 10-44: Haemophilus Influenzae Type B (HIB)-Vaccines Market (Million US$), 2011-2016
  • Figure 10-45: Haemophilus Influenzae Type B (HIB)-Forecast for Vaccines Market (Million US$), 2017-2022
  • Figure 10-46: Combos (Combination)-Vaccines Market (Billion US$), 2011-2016
  • Figure 10-47: Combos (Combination)-Forecast for Vaccines Market (Billion US$), 2017-2022
  • Figure 10-48: Polio-Vaccines Market (Million US$), 2011-2016
  • Figure 10-49: Polio-Forecast for Vaccines Market (Million US$), 2017-2022
  • Figure 10-50: Rotavirus Deaths Under Five Years of Age per 100 000 Population <5 Years of Age, 2013
  • Figure 10-51: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013
  • Figure 10-52: Rotavirus-Vaccines Market (Million US$), 2011-2016
  • Figure 10-53: Rotavirus-Forecast for Vaccines Market (Million US$), 2017-2022
  • Figure 10-54: Varicella-Vaccines Market (Billion US$), 2011-2016
  • Figure 10-55: Varicella-Forecast for Vaccines Market (Billion US$), 2017-2022
  • Figure 11-1: Influenza-Total Number of People Immunized (Million), 2011-2016
  • Figure 11-2: Influenza-Forecast for Total Number of People Immunized (Million), 2017-2022
  • Figure 11-3: Influenza-Number of Adults Immunized (Thousand), 2011-2016
  • Figure 11-4: Influenza-Forecast for Number of Adults Immunized (Thousand), 2017-2022
  • Figure 11-5: Influenza-Number of Infants Immunized (Thousand), 2011-2016
  • Figure 11-6: Influenza-Forecast for Number of Infants Immunized (Thousand), 2017-2022
  • Figure 11-7: Cervical Cancer-Number of People Immunized (Thousand), 2011-2016
  • Figure 11-8: Cervical Cancer-Forecast for Number of People Immunized (Thousand), 2017-2022
  • Figure 11-9: Zoster (Shingles)-Number of People Immunized (Thousand), 2011-2016
  • Figure 11-10: Zoster (Shingles)-Forecast for Number of People Immunized (Thousand), 2017-2022
  • Figure 11-11: MMRV and MMR-Total Number of People Immunized (Million), 2011-2016
  • Figure 11-12: MMRV and MMR-Forecast for Total Number of People Immunized (Million), 2017-2022
  • Figure 11-13: MMRV-Number of Adults Immunized (Thousand), 2011-2016
  • Figure 11-14: MMRV-Forecast for Number of Adults Immunized (Thousand), 2017-2022
  • Figure 11-15: MMR-Number of Pediatric (Infants) Immunized (Thousand), 2011-2016
  • Figure 11-16: MMR-Forecast for Number of Pediatric (Infants) Immunized (Thousand), 2017-2022
  • Figure 11-17: Pneumococcal-Total Number of People Immunized (Million), 2011-2016
  • Figure 11-18: Pneumococcal-Forecast for Total Number of People Immunized (Million), 2017-2022
  • Figure 11-19: Pneumococcal-Number of Adults Immunized (Thousand), 2011-2016
  • Figure 11-20: Pneumococcal-Forecast for Number of Adults Immunized (Thousand), 2017-2022
  • Figure 11-21: Pneumococcal-Number of Infants Immunized (Thousand), 2011-2016
  • Figure 11-22: Pneumococcal-Forecast for Number of Infants Immunized (Thousand), 2011-2016
  • Figure 11-23: Meningococcal-Total Number of People Immunized (Million), 2011-2016
  • Figure 11-24: Meningococcal-Forecast for Total Number of People Immunized (Million), 2017-2022
  • Figure 11-25: Meningococcal-Number of Adults Immunized (Thousand), 2011-2016
  • Figure 11-26: Meningococcal-Forecast for Number of Adults Immunized (Thousand), 2017-2022
  • Figure 11-27: Meningococcal-Number of Infants Immunized (Thousand), 2011-2016
  • Figure 11-28: Meningococcal-Forecast for Number of Infants Immunized (Thousand), 2017-2022
  • Figure 11-29: Hepatitis-Total Number of People Immunized (Million), 2011-2016
  • Figure 11-30: Hepatitis-Forecast for Total Number of People Immunized (Million), 2017-2022
  • Figure 11-31: Hepatitis-Number of Adults Immunized (Thousand), 2011-2016
  • Figure 11-32: Hepatitis-Forecast for Number of Adults Immunized (Thousand), 2017-2022
  • Figure 11-33: Hepatitis-Number of Infants Immunized (Thousand), 2011-2016
  • Figure 11-34: Hepatitis-Forecast for Number of Infants Immunized (Thousand), 2017-2022
  • Figure 11-35: TdaP and DTaP-Total Number of People Immunized (Million), 2011-2016
  • Figure 11-36: TdaP and DTaP-Forecast for Total Number of People Immunized (Million), 2017-2022
  • Figure 11-37: TdaP-Number of Adults Immunized (Thousand), 2011-2016
  • Figure 11-38: TdaP-Number of Adults Immunized (Thousand), 2017-2022
  • Figure 11-39: DTaP-Number of Infants Immunized (Thousand), 2011-2016
  • Figure 11-40: DTaP-Forecast for Number of Infants Immunized (Thousand), 2017-2022
  • Figure 11-41: Hib (Haemophilus Influenzae Type B)-Number of Infants Immunized (Million), 2011-2016
  • Figure 11-42: Hib (Haemophilus Influenzae Type B)-Forecast for Number of Infants Immunized (Million), 2017-2022
  • Figure 11-43: Combos (Combination Vaccines)-Number of Infants Immunized (Million), 2011-2016
  • Figure 11-44: Combos (Combination Vaccines)-Forecast for Number of Infants Immunized (Million), 2017-2022
  • Figure 11-45: Polio-Number of Infants Immunized (Million), 2011-2016
  • Figure 11-46: Polio-Forecast for Number of Infants Immunized (Million), 2017-2022
  • Figure 11-47: Rotavirus-Number of Infants Immunized (Million), 2011-2016
  • Figure 11-48: Rotavirus-Forecast for Number of Infants Immunized (Million), 2017-2022
  • Figure 11-49: Varicella-Number of Infants Immunized (Million), 2011-2016
  • Figure 11-50: Varicella-Forecast for Number of Infants Immunized (Million), 2017-2022
  • Figure 12-1: Influenza-Doses of Vaccines Administered (Million), 2011-2016
  • Figure 12-2: Influenza-Forecast for Doses of Vaccines Administered (Million), 2017-2022
  • Figure 12-3: Influenza-Doses of Adult Vaccines Administered (Million), 2011-2016
  • Figure 12-4: Influenza-Forecast for Doses of Adult Vaccines Administered (Million), 2017-2022
  • Figure 12-5: Influenza-Doses of Infant Vaccines Administered (Million), 2011-2016
  • Figure 12-6: Influenza-Forecast for Doses of Infant Vaccines Administered (Million), 2017-2022
  • Figure 12-7: Cervical Cancer (HPV)-Doses of Vaccines Administered (Million), 2011-2016
  • Figure 12-8: Cervical Cancer (HPV)-Forecast for Doses of Vaccines Administered (Million), 2017-2022
  • Figure 12-9: Zoster (Shingles)-Doses of Vaccines Administered (Million), 2011-2016
  • Figure 12-10: Zoster (Shingles)-Forecast for Doses of Vaccines Administered (Million), 2017-2022
  • Figure 12-11: MMRV and MMR-Doses of Vaccines Administered (Million), 2011-2016
  • Figure 12-12: MMRV and MMR-Forecast for Doses of Vaccines Administered (Million), 2017-2022
  • Figure 12-13: MMRV-Doses of Adult Vaccines Administered (Million), 2011-2016
  • Figure 12-14: MMRV-Forecast for Doses of Adult Vaccines Administered (Million), 2017-2022
  • Figure 12-15: MMR-Doses of Infant Vaccines Administered (Million), 2011-2016
  • Figure 12-16: MMR-Forecast for Doses of Infant Vaccines Administered (Million), 2017-2022
  • Figure 12-17: Pneumococcal-Doses of Vaccines Administered (Million), 2011-2016
  • Figure 12-18: Pneumococcal-Forecast for Doses of Vaccines Administered (Million), 2017-2022
  • Figure 12-19: Pneumococcal-Doses of Adult Vaccines Administered (Million), 2011-2016
  • Figure 12-20: Pneumococcal-Forecast for Doses of Adult Vaccines Administered (Million), 2017-2022
  • Figure 12-21: Pneumococcal-Doses of Infant Vaccines Administered (Million), 2011-2016
  • Figure 12-22: Pneumococcal-Forecast for Doses of Infant Vaccines Administered (Million), 2017-2022
  • Figure 12-23: Meningococcal-Doses of Vaccines Administered (Million), 2011-2016
  • Figure 12-24: Meningococcal-Forecast for Doses of Vaccines Administered (Million), 2017-2022
  • Figure 12-25: Meningococcal-Doses of Adult Vaccines Administered (Million), 2011-2016
  • Figure 12-26: Meningococcal-Forecast for Doses of Adult Vaccines Administered (Million), 2017-2022
  • Figure 12-27: Meningococcal-Doses of Infant Vaccines Administered (Million), 2011-2016
  • Figure 12-28: Meningococcal-Forecast for Doses of Infant Vaccines Administered (Million), 2017-2022
  • Figure 12-29: Hepatitis-Doses of Vaccines Administered (Million), 2011-2016
  • Figure 12-30: Hepatitis-Forecast for Doses of Vaccines Administered (Million), 2017-2022
  • Figure 12-31: Hepatitis-Doses of Adult Vaccines Administered (Million), 2011-2016
  • Figure 12-32: Hepatitis-Forecast for Doses of Adult Vaccines Administered (Million), 2017-2022
  • Figure 12-33: Hepatitis-Doses of Infant Vaccines Administered (Million), 2011-2016
  • Figure 12-34: Hepatitis-Forecast for Doses of Infant Vaccines Administered (Million), 2017-2022
  • Figure 12-35: TdaP and DTaP-Doses of Vaccines Administered (Million), 2011-2016
  • Figure 12-36: TdaP and DTaP-Forecast for Doses of Vaccines Administered (million), 2017-2022
  • Figure 12-37: TdaP-Doses of Adult Vaccines Administered (Million), 2011-2016
  • Figure 12-38: TdaP-Forecast for Doses of Adult Vaccines Administered (Million), 2017-2022
  • Figure 12-39: DTaP-Doses of Infant Vaccines Administered (Million), 2011-2016
  • Figure 12-40: DTaP-Forecast for Doses of Infant Vaccines Administered (Million), 2017-2022
  • Figure 12-41: Hib (Haemophilus Influenzae Type B)-Doses of Infant Vaccines Administered (Million), 2011-2016
  • Figure 12-42: Hib (Haemophilus Influenzae Type B)-Forecast for Doses of Infant Vaccines Administered (Million), 2017-2022
  • Figure 12-43: Polio-Doses of Infant Vaccines Administered (Million), 2011-2016
  • Figure 12-44: Polio-Forecast for Doses of Infant Vaccines Administered (Million), 2017-2022
  • Figure 12-45: Rotavirus-Doses of Infant Vaccines Administered (Million), 2011-2016
  • Figure 12-46: Rotavirus-Forecast for Doses of Infant Vaccines Administered (Million), 2017-2022
  • Figure 12-47: Varicella-Doses of Infant Vaccines Administered (Million), 2011-2016
  • Figure 12-48: Varicella-Forecast for Doses of Infant Vaccines Administered (Million), 2017-2022
  • Figure 13-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
  • Figure 13-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2015
  • Figure 14-1: Worldwide-GlaxoSmithKline, plc.'s Vaccines Sales (Billion US$), 2011-2016
  • Figure 14-2: Worldwide-Forecast for GlaxoSmithKline, plc.'s Vaccines Sales (Billion US$), 2017-2022
  • Figure 14-3: Worldwide-Merck & Co. Vaccines Sales (Billion US$), 2011-2016
  • Figure 14-4: Worldwide-Forecast for Merck & Co. Vaccines Sales (Billion US$), 2017-2022
  • Figure 14-5: Worldwide-Sanofi Pasteur's Vaccines Sales (Billion US$), 2011-2022
  • Figure 14-6: Worldwide-Forecast for Sanofi Pasteur's Vaccines Sales (Billion US$), 2017-2022
  • Figure 14-7: Worldwide-Pfizer, Inc.'s Vaccines Sales (Billion US$), 2011-2016
  • Figure 14-8: Worldwide-Forecast for Pfizer, Inc.'s Vaccines Sales (Billion US$), 2017-2022
  • Figure 14-9: Worldwide-Others Vaccines Sales (Billion US$), 2011-2016
  • Figure 14-10: Worldwide-Forecast for Others Vaccines Sales (Billion US$), 2017-2022
  • Figure 15-1: GSK Vaccine Product Pipeline
  • Figure 18-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
  • Figure 18-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
  • Figure 18-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
  • Figure 18-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
  • Figure 18-5: US Retail Clinics Expected to Surge by 2017

Lists of Tables

  • Table 2-1: Vaccine Recommendations
  • Table 2-2: Other Recommended Vaccines
  • Table 4-1: Global-Vaccines Market Share (Percent), 2011-2016
  • Table 4-2: Global-Forecast for Vaccines Market Share (Percent), 2017-2022
  • Table 4-3: Global-Adult Vaccines Market Share (Percent), 2011-2016
  • Table 4-4: Global-Adult Vaccines Market Share (Percent), 2017-2022
  • Table 4-5: Global-Pediatric (Infant) Vaccines Market Share (Percent), 2011-2016
  • Table 4-6: Global-Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2017-2022
  • Table 6-1: Global-People Immunized Share (Percent), 2011-2016
  • Table 6-2: Global-Forecast for People Immunized Share (Percent), 2017-2022
  • Table 6-3: Global-Adult Immunized Share (Percent), 2011-2016
  • Table 6-4: Global-Forecast for Adult Immunized Share (Percent), 2017-2022
  • Table 6-5: Global-Pediatric (Infant) Immunized Share (Percent), 2011-2016
  • Table 6-6: Global-Forecast for Pediatric (Infant) Immunized Share (Percent), 2017-2022
  • Table 8-1: Global-Doses of Vaccines Administered Share (Percent), 2011-2016
  • Table 8-2: Global-Forecast for Doses of Vaccines Administered Share (Percent), 2017-2022
  • Table 8-3: Global-Doses of Vaccines Administered to Adult Share (Percent), 2011-2016
  • Table 8-4: Global-Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2017-2022
  • Table 8-5: Global-Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011-2016
  • Table 8-6: Global-Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2017-2022
  • Table 13-1: Vaccines-Number of Reported Cases, 2011-2015
  • Table 13-2: Measles-Number of Cases Reported, 2001-2015
  • Table 13-3: Mumps-Number of Cases Reported, 2001-2015
  • Table 13-4: Rubella-Number of Cases Reported, 2001-2015
  • Table 13-5: Rubella (CRS)-Number of Cases Reported, 2001-2015
  • Table 13-6: Diphtheria-Number of Cases Reported, 2001-2015
  • Table 13-7: Tetanus (Neonatal)-Number of Cases Reported, 2001-2015
  • Table 13-8: Tetanus (Total)-Number of Cases Reported, 2001-2015
  • Table 13-9: Pertussis-Number of Cases Reported, 2001-2015
  • Table 13-10: Polio-Number of Cases Reported, 2001-2015
  • Table 13-11: Yellow Fever-Number of Cases Reported, 2001-2015
  • Table 13-12: Japanese Encephalitis-Number of Cases Reported, 2006-2015
  • Table 15-1: Merck Vaccine Product Pipeline
  • Table 15-2: Sanofi Vaccine Product Pipeline
  • Table 15-3: Pfizer Vaccine Product Pipeline
  • Table 16-1: Vaccine Mergers & Acquisitions
  • Table 18-1: United States Immunization Schedule
  • Table 18-2: Afghanistan Immunization Schedule
  • Table 18-3: Norway Immunization Schedule
  • Table 18-4: India Immunization Schedule
  • Table 18-5: Vietnam Immunization Schedule
  • Table 18-6: Worldwide-Total Future Deaths Averted through Vaccination (Million), 2011-2020
  • Table 18-7: Goal-Level Indicators, 2015 & 2020
  • Table 18-8: Improvement Strategies or Requirements-the Joint Commission and the Project's Collaborating Organizations
Back to Top